An AI model spotted a strange pattern in a virus's DNA that looks a little like CRISPR. Its makers cannot yet say what it ...

CRISPR Therapeutics (NasdaqGM:CRSP) has promoted Andrew J. Silver to Chief Financial Officer, effective October 19, 2026.

Isaacson argues that who patents, regulates, and profits from gene editing now matters as much as the science, because rewriting human heredity is no longer theoretical.

Learn more A concept image of a white brain on a blue background surrounded by colorful pills by Tanita_St via Shutterstock CRISPR Therapeutics' (CRSP) CFO recently resigned, potentially signaling ...

Spread the loveImagine looking in the mirror and seeing a younger version of yourself, not just cosmetically, but at a ...

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us ...

ERS Genomics Limited ('ERS Genomics'), the CRISPR licensing company, today announced that it has signed a non-exclusive ...

Application of the high-precision technique is part of a clinical trial to treat a genetic disease that can cause liver and ...

Called Cas12a2, the CRISPR system had some distinctive properties. Rather than editing cells’ DNA when prompted by a guide RNA, as CRISPR-Cas9 does, Cas12a2 indiscriminately shreds it, ultimately ...

A 2026 review summarizes advances in CRISPR-Cas9 precision, delivery and primary-cell engineering for genetic diseases and ...

In this interview, Prof. Samuel Sternberg discusses how studies of CRISPR-Cas systems led to the discovery of RNA-guided DNA ...